Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.33T
Market cap1.33T
Price-Earnings ratio
47.03
Price-Earnings ratio47.03
Dividend yield
0.47%
Dividend yield0.47%
Average volume
3.16M
Average volume3.16M
High today
$1,409.00
High today$1,409.00
Low today
$1,404.20
Low today$1,404.20
Open price
$1,416.50
Open price$1,416.50
Volume
254.29K
Volume254.29K
52 Week high
$1,475.25
52 Week high$1,475.25
52 Week low
$850.51
52 Week low$850.51

Stock Snapshot

With a market cap of 1.33T, Eli Lilly(LLY) trades at $1,405.04. The stock has a price-to-earnings ratio of 47.03 and currently yields dividends of 0.47%.

During the trading session on 2026-11-18, Eli Lilly(LLY) shares reached a daily high of $1,409.00 and a low of $1,404.20. At a current price of $1,405.04, the stock is +0.1% higher than the low and still -0.3% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 254.29K, versus its average volume of 3.16M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.

LLY News

Reuters 9h
Breakingviews - COMMENTARY: Eli Lilly’s $1.4 trln valuation is heavy with hope - Reuters

...

Breakingviews - COMMENTARY: Eli Lilly’s $1.4 trln valuation is heavy with hope - Reuters
The Motley Fool 17h
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

The global demand for next-generation metabolic treatments has sparked a fierce competition, forcing retail investors to decide between Eli Lilly & Co. (LLY -1....

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Simply Wall St 18h
Eli Lilly Showcased Its Obesity Pipeline, Is It Still 3% Undervalued?

Eli Lilly (LLY) just used ObesityWeek 2026 as a showcase for its cardiometabolic pipeline, unveiling detailed data on EloraTZP, retatrutide and oral GLP-1 pill...

Eli Lilly Showcased Its Obesity Pipeline, Is It Still 3% Undervalued?

Analyst ratings

81%

of 32 ratings
Buy
81.3%
Hold
12.5%
Sell
6.3%

More LLY News

Seeking Alpha 21h
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR

Rhythm Pharmaceuticals (RYTM) rose 5.4% amid a report that Eli Lilly (LLY) is evaluating two possible takeover targets in the obesity market, including Rhythm a...

Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Benzinga 21h
Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies

Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Mo...

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies
TipRanks 21h
Eli Lilly Enters Cancer Licensing Deal Worth $5.9 Billion

Eli Lilly (LLY) has signed an exclusive global licensing agreement with Cambridge, Massachusetts-based biotech firm Stipple Bio to discover and commercialize ca...

TipRanks 21h
Lilly Advances Next-Generation Obesity Drug Study as Investors Watch for Phase 3 Progress

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s NCT07900633 study is officially titled “A Phase 3,...

TipRanks 21h
Lilly Advances Lepodisiran Study as Investors Watch Lp(a) Pipeline

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s Phase 1 study, officially titled "A Phase 1, Open-...

TipRanks 21h
Lilly Updates Early Eloralintide Study as Investors Watch Its Obesity Pipeline

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company (LLY) has updated a Phase 1 study titled...

TipRanks 23h
Eli Lilly’s Growth Outlook Strengthened by Pipeline, Oncology Expansion and Calytrix Acquisition; $1,650 Price Target Maintained

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,650.00. Evan Seigerman’s rating is based on...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.